{"id":57802,"date":"2023-07-25T19:04:36","date_gmt":"2023-07-25T17:04:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/"},"modified":"2023-07-25T19:04:36","modified_gmt":"2023-07-25T17:04:36","slug":"united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/","title":{"rendered":"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Denovo Biopharma LLC identified a novel genetic biomarker &#8211; Denovo Genomic Marker 7 (DGM7<sup>TM<\/sup>) &#8211; based on data from a prior clinical trial in patients with recurrent disease &#8211; believed to predict responders to DB107<\/b><\/li>\n<li>\n<b>FDA authorized a Phase 2 study of DB107 for the treatment of patients with newly diagnosed high grade glioma<\/b><\/li>\n<li>\n<b>Study will explore safety and efficacy using multiple localized and systemic dosing regimens differentially in MGMT methylated and unmethylated populations<\/b><\/li>\n<li>\n<b>Aim is to assess DGM7 as a predictive biomarker for DB107, and the subsequent degree of efficacy<\/b><\/li>\n<\/ul>\n<p>LONDON &amp; CHICAGO &amp; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/anova?src=hash\" target=\"_blank\" rel=\"noopener\">#anova<\/a>&#8211;Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating the development of promising treatments to market announced the FDA authorization of a Phase II clinical trial to re-assess a targeted treatment in light of newly discovered pharmacogenomic predictor data in patients with newly diagnosed high-grade glioma (HGG).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/5\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/21\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/5\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/22\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\"><\/a><\/p>\n<p>\nDenovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, acquired Toca 511 and Toca FC (now collectively known as DB107) from Tocagen in 2020, with the aim of identifying one or more pharmacogenomic predictors for DB107 efficacy using its proprietary biomarker discovery platform.<\/p>\n<p>\nIn December 2021 Denovo Biopharma announced discovery of a novel genetic biomarker, Denovo Genomic Marker 7 (DGM7<sup>TM<\/sup>), by leveraging Tocagen\u2019s randomized 403-patient Phase 3 study in recurrent HGG that had negative results overall, but that had subsets of patients who received clear benefit. DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.<\/p>\n<p>\nThis year, Anova Enterprises, Inc. assembled a team of key opinion leaders from the University of California at San Diego (UCSD), University of California at San Francisco (UCSF), the University of Southern California (USC) and Denovo Biopharma to explore the best way to confirm the efficacy of DB107 in patients with HGG who have the DGM7 biomarker. The resulting Phase 2 study design has been authorized to proceed by the U.S. FDA, literally bringing a treatment \u201cback from the dead\u201d to help patients in need.<\/p>\n<p>\nThe Phase 2 study of DB107 will investigate the impact of giving multiple doses of DB107 both directly at time of surgery and intravenously (IV). The study also stratifies patients to more easily identify those individuals who benefit from treatment from those who do not. \u201cFDA authorization of the study of DB107 is another important milestone for Denovo as we work to bring this retroviral replicating vector (RVV) back into clinical development\u201d said Matthew A. Spear, M.D., Chief Medical Officer &amp; Chief Development Officer, Denovo Biopharma. \u201cOur dedicated team worked diligently to identify the biomarker which predicts response to DB107 and it will be exciting to potentially confirm our work in this prospective clinical trial.\u201d<\/p>\n<p>\nAnova Enterprises, Inc. (Anova) will manage the study using its transformative AnovaOS\u2122 technology. AnovaOS\u2122 is the industry\u2019s first collaborative \u2018learning system\u2019. \u201cThis is exactly the sort of opportunity Anova wants to deliver in the marketplace\u201d said Martin Walsh, President at Anova. \u201cWe regularly see patients responding to treatments in studies that fail in large randomized patient populations. Identifying predictive biomarkers such as DGM7 and confirming results in smaller, targeted patient populations is the way toward better and more cost effective treatments.\u201d<\/p>\n<p>\nThe Phase 2 clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107 when added to standard-of-care (SOC) provides clinical benefit to newly diagnosed HGG when compared to historical performance documented in well controlled clinical trials published in the peer reviewed literature. The trial is expected to enroll approximately 70 adult patients with newly diagnosed HGG, and the primary endpoint of the trial will be progression free survival (PFS).<\/p>\n<p>\n\u201cI am excited to see DB107 heading back into the clinic\u201d said Noriyuki Kasahara, MD, PhD, Principal Investigator, Brain Tumor Research Center (BTRC) at University of California, San Francisco (UCSF). \u201cOutcomes in patients newly diagnosed with HGG are essentially unchanged for 40 years and confirming DB107 works in patients with the DGM7 biomarker may change outcomes in those patients for the better\u201d<\/p>\n<p>\n\u201cOur partnership with Denovo Biopharma, UCSD, UCSF and USC is another example of Anova\u2019s commitment to improving access to promising new treatments for patients in need, in diseases where patients are often left with limited treatment options\u201d said Chris Beardmore, CEO at Anova. \u201cBy fixing what is broken in clinical research we can conduct better studies and deliver the right treatments to the right patients.\u201d<\/p>\n<p>\nTo find out more contact <a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;o&#x3a;i&#x6e;&#102;&#x6f;&#46;&#x75;&#115;&#x40;&#97;n&#111;v&#x61;e&#x76;i&#x64;&#101;&#x6e;&#99;&#x65;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x6e;&#x66;&#111;&#46;&#117;s&#64;&#x61;&#x6e;&#x6f;&#x76;&#97;&#101;vi&#x64;&#x65;&#x6e;&#x63;&#101;&#46;co&#x6d;<\/a><\/p>\n<p class=\"bwalignc\">\n<b>ENDS<\/b><\/p>\n<p>\n<b>About Anova<\/b><\/p>\n<p>\nAnova Enterprises, Inc. (Anova) is technology enabled research organization committed to accelerating clinical development with is proprietary technology platform (AnovaOS\u2122). Anova, in partnership with biopharmaceutical companies developing promising products designed to treat patients with serious and life -threatening disease. By fixing what is broken in clinical research, Anova speeds promising new treatments to market, at reduced cost and for a larger number of patients. We kickstart the development of treatments as no one else can do. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.anovaevidence.com&amp;esheet=53474941&amp;newsitemid=20230725732987&amp;lan=en-US&amp;anchor=www.anovaevidence.com&amp;index=1&amp;md5=1677ce91137db549b83692bb67c27c8c\" rel=\"nofollow noopener\" shape=\"rect\">www.anovaevidence.com<\/a>.<\/p>\n<p>\n<b>About Denovo Biopharma<\/b><\/p>\n<p>\nDenovo Biopharma LLC is a clinical-stage biopharmaceutical company that uses novel biomarker approaches to re-evaluate medicines that have failed in broad patient populations. The company seeks to discover genomic biomarkers correlated with patients&#8217; responses to drug candidates retrospectively. Denovo executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo has 8 late clinical stage drugs in its pipeline. These address major unmet medical needs in oncology and CNS diseases, most of which are first-in-class drugs with global rights. It has two biomarker-guided late-stage ongoing trials &#8212; a Phase 3 trial in glioblastoma (GBM) for its DB102 asset and a Phase 2b trial for its DB104 asset. For additional information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.denovobiopharma.com%2F&amp;esheet=53474941&amp;newsitemid=20230725732987&amp;lan=en-US&amp;anchor=www.denovobiopharma.com&amp;index=2&amp;md5=614c21e2a720016293b87cd8cc79e291\" rel=\"nofollow noopener\" shape=\"rect\">www.denovobiopharma.com<\/a>.<\/p>\n<p>\n<b>About Denovo\u2019s RRV Platform and DB107<\/b><\/p>\n<p>\nDB107 is an innovative approach utilizing a proprietary gene therapy platform, recombinant retroviral vector (RRV) bearing cytosine deaminase, combined with a prodrug of 5-FU (5-FC), to selectively infect and kill cancer cells while stimulating a robust and durable anti-cancer immune response against a tumor with minimal toxicity. DB107 has been tested clinically in solid tumors including recurrent high-grade GBM and colorectal cancer, most recently in a randomized 403-patient Phase 3 trial. DB107 received Orphan Drug Designation in GBM from the FDA and EMA, and Fast Track Designation from the FDA.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>MEDIA<\/b><br \/><b>Martin Walsh, Co-Founder and President<\/b><br \/>Anova Enterprises, Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;t&#111;&#x3a;&#109;&#x61;r&#116;&#x69;&#110;&#x40;a&#x6e;&#x6f;&#118;&#x61;e&#x76;i&#100;&#x65;&#110;&#x63;e&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#109;&#x61;&#114;&#x74;&#105;&#x6e;&#64;&#x61;&#110;&#x6f;&#118;&#x61;&#101;&#x76;&#105;&#x64;&#101;&#x6e;&#99;&#x65;&#46;&#x63;&#111;&#x6d;<\/a><\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.anovaevidence.com&amp;esheet=53474941&amp;newsitemid=20230725732987&amp;lan=en-US&amp;anchor=www.anovaevidence.com&amp;index=3&amp;md5=e5d52e87ebeda2d49a1210ff7a986c9d\" rel=\"nofollow noopener\" shape=\"rect\">www.anovaevidence.com<\/a><br \/>Twitter feed at @anovaevidence<br \/>\n<br \/>Follow Anova at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanovaevidence&amp;esheet=53474941&amp;newsitemid=20230725732987&amp;lan=en-US&amp;anchor=www.linkedin.com%2Fcompany%2Fanovaevidence&amp;index=4&amp;md5=c50e1926665a68ab37fdb1efc2dc52fa\" rel=\"nofollow noopener\" shape=\"rect\">www.linkedin.com\/company\/anovaevidence<\/a><\/p>\n<p>\n<b>Michael F. Haller, Chief Business Officer<\/b><br \/>Denovo Biopharma LLC<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o:&#109;&#104;&#x61;&#x6c;le&#114;&#64;&#x64;&#x65;no&#118;&#x6f;&#x62;&#x69;o&#112;&#104;&#x61;&#x72;&#x6d;a&#46;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#104;&#x61;&#108;l&#x65;&#114;&#64;&#x64;&#101;&#x6e;&#x6f;v&#x6f;&#98;i&#x6f;&#112;&#x68;&#x61;r&#x6d;&#97;&#46;&#x63;&#111;m<\/a><\/p>\n<p>\n<b>Anova Enterprises, Inc.<\/b><br \/>(224) 218-2408<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;&#x3a;i&#110;&#x66;o&#46;&#x75;&#x73;&#64;&#97;&#x6e;o&#118;&#x61;&#x65;v&#105;&#x64;&#x65;&#110;&#x63;&#x65;&#46;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x6e;&#x66;o&#46;&#x75;s&#64;&#x61;&#x6e;o&#118;&#x61;e&#118;&#x69;&#x64;e&#110;&#x63;e&#46;&#x63;&#x6f;&#109;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Denovo Biopharma LLC identified a novel genetic biomarker &#8211; Denovo Genomic Marker 7 (DGM7TM) &#8211; based on data from a prior clinical trial in patients with recurrent disease &#8211; believed to predict responders to DB107 FDA authorized a Phase 2 study of DB107 for the treatment of patients with newly diagnosed high grade glioma Study &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57802","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Denovo Biopharma LLC identified a novel genetic biomarker &#8211; Denovo Genomic Marker 7 (DGM7TM) &#8211; based on data from a prior clinical trial in patients with recurrent disease &#8211; believed to predict responders to DB107 FDA authorized a Phase 2 study of DB107 for the treatment of patients with newly diagnosed high grade glioma Study ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-25T17:04:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/21\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma\",\"datePublished\":\"2023-07-25T17:04:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/\"},\"wordCount\":1118,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230725732987\\\/en\\\/828167\\\/21\\\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/\",\"name\":\"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230725732987\\\/en\\\/828167\\\/21\\\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\",\"datePublished\":\"2023-07-25T17:04:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230725732987\\\/en\\\/828167\\\/21\\\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230725732987\\\/en\\\/828167\\\/21\\\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/","og_locale":"en_US","og_type":"article","og_title":"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma - Pharma Trend","og_description":"Denovo Biopharma LLC identified a novel genetic biomarker &#8211; Denovo Genomic Marker 7 (DGM7TM) &#8211; based on data from a prior clinical trial in patients with recurrent disease &#8211; believed to predict responders to DB107 FDA authorized a Phase 2 study of DB107 for the treatment of patients with newly diagnosed high grade glioma Study ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/","og_site_name":"Pharma Trend","article_published_time":"2023-07-25T17:04:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/21\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma","datePublished":"2023-07-25T17:04:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/"},"wordCount":1118,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/21\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/","url":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/","name":"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/21\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg","datePublished":"2023-07-25T17:04:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/21\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230725732987\/en\/828167\/21\/ANOVA-Logo-Final-%28for-use-on-light-backgrounds%29-01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/united-states-food-and-drug-administration-fda-authorizes-phase-2-study-of-db107-in-promising-turn-around-of-targeted-treatment-to-treat-newly-diagnosed-high-grade-glioma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57802"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57802\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}